1541P Real-world Data from Patients with Gastrointestinal Stromal Tumors (GIST) Treated in Dutch GIST Expertise Centers

Introduction of tyrosine kinase inhibitors (TKIs) led to a greatly improved survival of advanced gastrointestinal stromal tumors (GIST). Imatinib was registered as first line palliative therapy in 2001 with a median progression free survival (mPFS) of 20.3 months. Furthermore, sunitinib and regorafenib have shown efficacy in the registration studies (mPFS of 5.6 months and 4.8 months resp.). Still, development of novel agents is needed to overcome TKI resistant GIST. The aim of this retrospective cohort study was to provide real-world response and survival data of approved TKIs to serve as reference point for new agents under development.